Market Overview

UPDATE: Deutsche Bank Reiterates on Alexion Pharmaceuticals Ahead of Asfotase Alfa Launch

Share:
Related ALXN
The Market In 5 Minutes
Exclusive: Alexion Responds To Government Probe
Biotechs On A Hot Streak, And Could Be 'Cooking With Gas' (Investor's Business Daily)

In a report published Monday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and raised the price target from $125.00 to $205.00.

In the report, Deutsche Bank noted, “The next new product launch for Alexion is Asfotase Alfa for severe Hypophosphatasia (HPP). Our deep dive into the drug suggests the market is bigger vs. street expectations. We also updated our Soliris & expense assumptions to more accurately reflect company guidance. We believe incidence is greater than literature suggests & model 1/25,000 in US & 1/50,000 ex-US of severe pediatric HPP.”

Alexion Pharmaceuticals closed on Friday at $163.63.

Latest Ratings for ALXN

DateFirmActionFromTo
Jul 2017Morgan StanleyMaintainsOverweight
May 2017Morgan StanleyUpgradesEqual-WeightOverweight
Mar 2017UBSInitiates Coverage OnBuy

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!